Neuro-oncology Regimens

The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available.Use of these documents is the responsibility of the prescribing clinician and is subject to the HSE.ie terms of use.

Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie.

Neuro-oncology Regimens

Regimen Name Indication

Procarbazine Lomustine and VinCRIStine (PCV) Therapy

Regimen

00379a

Adjuvant treatment of Grade II glioma administered after radiotherapy.

00379b

Palliative treatment for recurrent high grade gliomas.

Temzolomide RT and Adjuvant Therapy

Regimen

00334a

Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation


Temozolomide Recurrent Therapy

Regimen

00342a

Adult patients with Grade III or IV malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.